Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: Severity-dependent treatment of the overactive bladder

BJU International

Volumn 94, Issue 6, 2004, Pages 821-827

  Preik, Michael ^a   Albrecht, Detlef ^b   O'Connell, Martin ^b   Hampel, Christian ^c   Anderson, Rodney ^d  

^a JANSSEN CILAG GMBH   (Germany)

^b ALZA CORPORATION   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticholinergic; Controlled release; OROS ; Oxybutynin; Pharmacokinetics; Urge urinary incontinence

Indexed keywords

OROS; OXYBUTYNIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; URINARY INCONTINENCE;

EID: 8144226787     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05040.x     Document Type: Article

References (22)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167-78
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff JW, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
3. Nitti VW. Clinical impact of overactive bladder. Urology 2002; 4: 2-6
4. Michel MC. A benefit-risk assessment of extended-release oxybutynin. Drug Saf 2002; 25: 867-76
5. Richelson E, Elliott D. Advances in medical management of overactive bladder. Mayo Clin Proc 2003; 78: 681-3
6. Lai HH, Boone TB, Appell RA. Selecting a medical therapy for overactive bladder. Urology 2002; 4: 28-37
7. Thüroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-7
8. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 52: 409-17
9. Dmochowski RR, Staskin DR. Advances in drug delivery: Improved bioavailability and drug effect. Curr Urol Rep 2002; 3: 439-44
10. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
11. Douchamps J, Derenne F, Stockis A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol, 1988; 35: 515-20
12. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39: 289-96
13. Dmochowski RR, Kell S, Staskin D. Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Expert Opin Pharmacother 2002; 3: 443-54
14. Gupta SK, Sathyan G, Lindemulder EA, Ho PL, Sheiner L, Aarons L. Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationship. Clin Pharmacol Ther 1999; 65: 672-84
15. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161: 1809-12
16. Appell RA. The newer antimuscarinic drugs: Bladder control with less dry mouth. Cleve Clin J Med 2002; 69: 761-9
17. Quay DRP. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-5
18. Chappie CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002; 60 (Suppl 5A): 82-9
19. MacDiarmid SA. Overactive bladder: Improving the efficacy of anticholinergics by dose escalation. Current Urol Reports 2003; 4: 446-51
20. Gleason DM, Susset J, White C et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 420-3
21. Versi E, Appell R, Mobley D et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstetrics Gynecol 2000; 95: 718-21
22. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and toerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder. Results of the OPERA Trial. Mayo Clin Proc 2003; 78: 687-95